Allergan chief Saunders takes a painful $2.5B hit on an ugly PhIII flop
Now that Allergan chief Brent Saunders has stared down the activists — for now, anyway — the company is back with a $2.5 billion writedown for their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
